fosquidone

Also Known As:

GR 63178; GR 63178A; GR-63178; GR-63178A; NSC D611615; NSC-D611615; fosquidone sodium

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

1.	Neoplasms (Cancer) 05/01/1992 - "A total of 91 eligible patients with metastatic cancer have been treated in a series of phase II trials of the novel pentacyclic pyrroloquinone, fosquidone. " 04/01/1992 - "A total of 61 eligible patients with metastatic cancer have been treated in a series of Phase II trials of the novel pentacyclic pyrroloquinone, fosquidone. "
2.	Melanoma (Melanoma, Malignant) 05/01/1992 - "Phase II trials of fosquidone (GR63178A) in carcinoma of the breast, head and neck, ovary and melanoma."
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/01/1992 - "Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer. "
4.	Carcinoma (Carcinomatosis) 05/01/1992 - "Phase II trials of fosquidone (GR63178A) in carcinoma of the breast, head and neck, ovary and melanoma."
5.	Ovarian Neoplasms (Ovarian Cancer) 05/01/1990 - "Activity of GR30921X (NSC 382057) and GR63178A (NSC D611615) in human ovarian cancer lines."